

Resignation of member of the Board of Director

Milan, 19 March 2015 – MolMed S.p.A. (MLM.MI) announces that, today Prof. Riccardo Cortese communicated his resignation, effective from 1st April 2015, from the office of independent non-executive member of the Board of Directors and of member of the Remuneration committee. Prof. Cortese does not hold any Company shares.

In announcing his resignation Prof. Cortese stated: *“It is with regret that my resignation really comes at a time in which MolMed’s pioneering work in cell therapy has taken off worldwide, becoming the new frontier in oncology. The main reason is private, since I have to travel more frequently to the US, and secondly, due to my recent commitment within a newly formed Biotech company dedicated to the development of new therapies in the field of aging”.*

The Board of Directors, while accepting the resignation, addressed sincere thanks to Prof. Riccardo Cortese for his commitment and valuable contribution to the Company during the period in which he held the position of Director.

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes two antitumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company’s shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)

For further information:

Marina Del Bue

General Manager Corporate Governance & Administration

Investor Relations Director *ad int.*

MolMed S.p.A.

phone: +39 02 21277.411

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325

info@molmed.com - www.molmed.com

Share capital € 11,019,314.98 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159



PRESS RELEASE

Press agent

Federico Ferrari

SEC Relazioni Pubbliche e Istituzionali srl

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: ferrari@secrp.it

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.